To verify the role of IGF2BP3 in post-transcriptional modification of SRD5A3 during cisplatin resistance development in bladder cancer, RIP assays revealed enrichment of SRD5A3 in anti-IGF2BP3 antibody fraction, underscoring the interaction between IGF2BP3 and SRD5A3 mRNA. Here, IGF2BP3 is linked to urinary bladder carcinoma.